Measured in dollars, this year is closer to last year than the headlines would indicate.
And once again, GEN is highlighting 10 biopharmas that have generated the most buzz about being bought out in recent months, based on Top acquires topped to investors and comments in news outlets. For each company mentioned, this list explains where talk of acquisitions has surfaced, and why.
Small- to medium-capitalization biopharmas continue to dominate Wall Street speculation about top buyout prospects by showing promise for reasons ranging from approvals for new products and rising sales to successful clinical programs in indications that are expected to generate billions in new revenues.
AveXis generated positive vibes about its ability to attract a buyer this year thanks to positive clinical results.
So persistent is the narrative that BioMarin Pharmaceutical is a takeover target that the rare disease drug developer has appeared on every such list compiled by GEN —from the first such list inwhen Roche was said to have cast its eyes on the company, through last year's list. Capital Markets predicted that: Also attractive, Campbell added, were two late-stage pipeline candidates: Over the coming year, bluebird is expected to file Top acquires topped approvals for both.
Those numbers are expected to rise insince Rubraca is expected to launch in Europe and win approval for at least one additional indication—maintenance treatment in women with platinum-sensitive recurrent ovarian cancer, for which Top acquires topped has been granted priority review by the FDA.
Rubraca is in four other Phase III trials: GlobalData Healthcare cited the oncology focus of Clovis as well as bluebird bio and Puma Biotechnology as a driver of takeover talk, along with the fact many biopharma giants are now flush with cash after the overhaul of U. A growing investor appetite for oncology-focused biopharmas has kept Incyte on numerous takeover-target lists.
Another asset of interest to investors is Iclusig ponatinibfor which Incyte has an exclusive license signed in with Ariad Pharmaceuticals since acquired by Takeda Pharmaceutical to develop and commercialize Iclusig in Europe and other ex-U. In Aprilthe FDA issued a Complete Response Letter declining to approve the rheumatoid arthritis candidate Incyte co-developed with Eli Lilly, Olumiant baricitinibTop acquires topped additional clinical data.
But in December, after talks with the agency, Lilly re-filed the U. Puma achieved market authorization in an indication targeted by the company that markets Herceptin.
The prospect of a blockbuster drug for major depressive disorder MDD has further catapulted Sage Therapeutics to takeover-target status recently, following two positive announcements of clinical data since November.
Another pipeline prospect for Sage is brexanolone.
On November 9, Top acquires topped disclosed results from Phase III studies of in severe and moderate postpartum depression, showing statistically significant reductions in HAM-D total score compared with placebo at 60 hours. Capital Markets in The Motley Fool.
Tesaro is one of three companies with approved poly ADP-ribose polymerase PARP inhibitor treatments on the market, accounting for its interest among market-watchers scouring for biopharma buyout candidates. Capital Markets wrote in The Motley Fool.